[A20-95] Baricitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V

Last updated 15.02.2021

Project no.:

Commission awarded on 16.11.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Skin and hair


Adults with moderate to severe atopic dermatitis who are candidates for systemic therapy

Result of dossier assessment:

Added benefit not proven for either of both research questions (longterm/continued systemic therapy indicated or not indicated)


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form